Finally, treatment with ruxolitinib, the kinase inhibitor preferentially impairing activity JAK1 and JAK2, showed therapeutic efficacy against diverse T-cell lymphomas, particularly the ones with evidence of JAK/STAT mutations or even STAT3 activation, foremost in T-LGL (55). This evidence concerns the gene JAK2 and T-cell non-Hodgkin lymphoma.